Cargando…
Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials
The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 patients...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493745/ https://www.ncbi.nlm.nih.gov/pubmed/23226738 http://dx.doi.org/10.3892/etm.2012.690 |
_version_ | 1782249318295535616 |
---|---|
author | ZHANG, JIAN ZHANG, WEIQING HUANG, SHAOHONG LI, HUI LI, YUN CHEN, HUIGUO WU, WEIBING ZHOU, WEI WANG, CUIPING LIAO, HONGYING GU, LIJIA |
author_facet | ZHANG, JIAN ZHANG, WEIQING HUANG, SHAOHONG LI, HUI LI, YUN CHEN, HUIGUO WU, WEIBING ZHOU, WEI WANG, CUIPING LIAO, HONGYING GU, LIJIA |
author_sort | ZHANG, JIAN |
collection | PubMed |
description | The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 patients as maintenance treatment, while the remaining patients received a placebo or observation only. The meta-analysis was performed using Reviewer Manager Version 5.12 software. Compared with the control group, maintenance erlotinib improved progression-free survival (PFS) and overall survival (OS) with moderate heterogeneity. Results from the random effects model analysis for OS were not in concordance with the difference observed in the fixed effects model analysis. Administration of erlotinib only after chemotherapy obtained a higher objective response rate (ORR). Safety analyses indicated a slight increase in side-effects. The most common adverse events (AEs) were diarrhea and rash, which were usually manageable. There was no significant difference in treatment-related deaths. Erlotinib produced significant clinical benefits with acceptable toxicity as a maintenance strategy in patients with unresectable NSCLC, particularly when sequentially administered with chemotherapy. However, more well-designed randomized control trials (RCTs) are required to identify patients that may derive greater benefits from maintenance with erlotinib, and whether the use of erlotinib as maintenance therapy is more efficient than second-line treatment should also be investigated. |
format | Online Article Text |
id | pubmed-3493745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-34937452012-12-06 Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials ZHANG, JIAN ZHANG, WEIQING HUANG, SHAOHONG LI, HUI LI, YUN CHEN, HUIGUO WU, WEIBING ZHOU, WEI WANG, CUIPING LIAO, HONGYING GU, LIJIA Exp Ther Med Articles The aim of this study was to evaluate the efficacy and safety of erlotinib as maintenance therapy in patients with unresectable non-small cell lung cancer (NSCLC) by evidence-based methodology. Six eligible studies including 4,372 patients were analyzed. Erlotinib was administered to 2,191 patients as maintenance treatment, while the remaining patients received a placebo or observation only. The meta-analysis was performed using Reviewer Manager Version 5.12 software. Compared with the control group, maintenance erlotinib improved progression-free survival (PFS) and overall survival (OS) with moderate heterogeneity. Results from the random effects model analysis for OS were not in concordance with the difference observed in the fixed effects model analysis. Administration of erlotinib only after chemotherapy obtained a higher objective response rate (ORR). Safety analyses indicated a slight increase in side-effects. The most common adverse events (AEs) were diarrhea and rash, which were usually manageable. There was no significant difference in treatment-related deaths. Erlotinib produced significant clinical benefits with acceptable toxicity as a maintenance strategy in patients with unresectable NSCLC, particularly when sequentially administered with chemotherapy. However, more well-designed randomized control trials (RCTs) are required to identify patients that may derive greater benefits from maintenance with erlotinib, and whether the use of erlotinib as maintenance therapy is more efficient than second-line treatment should also be investigated. D.A. Spandidos 2012-11 2012-08-31 /pmc/articles/PMC3493745/ /pubmed/23226738 http://dx.doi.org/10.3892/etm.2012.690 Text en Copyright © 2012, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles ZHANG, JIAN ZHANG, WEIQING HUANG, SHAOHONG LI, HUI LI, YUN CHEN, HUIGUO WU, WEIBING ZHOU, WEI WANG, CUIPING LIAO, HONGYING GU, LIJIA Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials |
title | Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials |
title_full | Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials |
title_fullStr | Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials |
title_full_unstemmed | Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials |
title_short | Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials |
title_sort | maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493745/ https://www.ncbi.nlm.nih.gov/pubmed/23226738 http://dx.doi.org/10.3892/etm.2012.690 |
work_keys_str_mv | AT zhangjian maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT zhangweiqing maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT huangshaohong maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT lihui maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT liyun maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT chenhuiguo maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT wuweibing maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT zhouwei maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT wangcuiping maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT liaohongying maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials AT gulijia maintenanceerlotinibimprovesclinicaloutcomesofunresectableadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials |